Metabolic surgery

Czech version

Authors: M. Fried
Authors‘ workplace: Centrum pro léčbu obezity a metabolických poruch OB kliniky a 1. lékařské fakulty UK Praha, přednosta prof. MU Dr. Martin Fried, CSc.
Published in: Vnitř Lék 2010; 56(10): 1065-1068
Category: Obesity 2010

Overview

In the beginning of the 21st century obesity still represents health, social and economical threat for most of economically wealthy countries worldwide. Estimated direct costs for obesity and related comorbidities treatment exceed 5% of the total health care spendings both in the US and in European Union. However, in addition there are obesity related indirect costs linked to more frequent work sickness leave, higher unemployment rates and owerall lower productivity of obese patients. Surgical treatment of obesity (bariatric surgery) is the most effective long‑term treatment modality to those suffering from higher degrees of obesity. Bariatric surgery has not only positive effect on weight loss, but is also extremely effective in improving or resolving many of obesity‑related comorbidities. T2DM may serve as excellent example of metabolic, obesity‑related comorbidity which can be treated with bariaric- metabolic procedure even without direct relation to weight loss. In such cases bariatric surgery evolves into metabolic surgery. Thus metabolic operations (namely from the malabsorptive end) deeply influence hormonal secretion especially in the proximal part of small bowel, change parametres of entero‑insular axis and have positive influence on insulin secretion, sensitivity and on the entire complex of glucose tolerance. Nowadays we can witness dramatic changes in perceprion of T2DM from bariatric surgeons, diabetologists, and many other medical specialists. T2DM evolved from primarily medical disease into a conditin where surgeon may play much more active role in the management of diabetic patient. However it has to be stressed, that metabolic treatment of T2DM and other metabolic disorders neccessitates multi‑disciplinary approach and collaboration and that surgeon should play very important role as a multidisciplinary team member, however metabolic surgery should not be sees as standing alone treatment modality.

Key words:
bariatric surgery – metabolic surgery – incretins – type 2 diabetes mellitus – obesity – metabolic disorders

Sources

1. Fry J, Finley W. The prevalence and costs of obesity in the EU. Proc Nutr Soc 2005; 64: 359– 362.

2. Kannan H, Thompson S, Bolge SC. Economic and humanistic outcomes associated with comorbid type- 2 diabetes, high cholesterol, and hypertension among individuals who are overweight or obese. J Occup Environ Med 2008; 50: 542– 549.

3. Fried M, Hainer V, Basdevant A et al. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Obes Surg 2007; 17: 260– 270.

4. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult‑ onset diabetes mellitus. Ann Surg 1995; 222: 339– 352.

5. National Conference of State Legislatures. Vol. 13, No. 32. Available from: www.ncsl.org.

6. Buchwald H. Consensus Conference Panel. Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third‑ party payers. J Am Coll Surg 2005; 200: 593– 604.

7. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta‑analysis. JAMA 2004; 292: 1724– 1737.

8. Cancello R, Henegar C, Viguerie N et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery‑induced weight loss. Diabetes 2005; 54: 2277– 2286.

9. Scopinaro N, Marinari GM, Camerini G et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long‑term follow‑up study. Diabetes Care 2005; 28: 2406– 2411.

10. Fried M, Ribaric G, Buchwald JN et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/ m2: an integrative review of early studies. Obes Surg 2010; 20: 776– 790.

11. Guidone C, Manco M, Valera‑ Mora E et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025– 2031.

12. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care 2006; 9: 497– 507.

13. Chan JM, Rim EB, Colditz GA et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabet Care 1994; 17: 961– 969.

14. Colditz GA, Willett WC, Rotnitzky A et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481– 486.

15. Banegas JR, López- García E, Gutiérrez- Fisac JL et al. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr 2003; 57: 201– 208.

16. Poulose BK, Holzman MD, Zhu Y et al. National variations in morbid obesity and bariatric surgery use. J Am Coll Surg 2005; 201: 77– 84.

17. Adams KF, Schatzkin A, Hartus TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763– 768.

18. Drenick EJ, Bale GS, Seltzer F et al. Excessive mortality and cause of death in morbidly obese men. JAMA 1980; 243: 443– 444.

19. Scopinaro N, Papadia F, Marinari G et al. Long‑term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/ m2. Obes Surg 2007; 17: 185– 192.

20. Buchwald H, Varco RL. Metabolic Surgery. New York: Grune & Stratton 1978.

21. Fried M, Svačina Š, Owen K. Bariatrická chirurgie a diabetes. In: Svačina Š (ed). Trendy soudobé diabetologie 10. Praha: Galén 2005.

22. Svačina S. Význam inkretinů při metabolických účincích bariatrické léčby obezity. In: Haluzík M, Svačina S (eds). Inkretinová léčba diabetu. Praha: Mladá Fronta 2010: 41– 51.

23. Müllerová D et al. Obezita. Praha: Mladá Fronta 2009.